Carolina Reduzzi: CTCs – From Prognosis to Treatment Selection?
Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine and Director of Cristofanilli CTC laboratory at Weill Cornell Medicine, shared a post on LinkedIn:
“CTCs: from prognosis to treatment selection?
In our analysis of the PACE study, published on CCR AACR Journals Baseline CTC enumeration (≥5 CTCs, stage IV-aggressive) identifies patients with extended PFS from fulvestrant+palbociclib (F+P) or F+P+avelumab vs F alone.
The impact was confirmed also after adjusting for clinical and mutational status.”
Title: Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
Authors: Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane L. Meisel, Kathy Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya A. Reid, Naomi Ko, Yuan Liu, Eric Gauthier, Harold J. Burstein, Michelle DeMeo, Sara M. Tolaney, Meredith M. Regan, Massimo Cristofanilli, Erica L. Mayer
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023